Equities research analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to post earnings of ($0.07) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The firm is expected to announce its next earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.40). For the next financial year, analysts anticipate that the company will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.83) to ($0.31). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02.
EVOK has been the subject of several recent research reports. HC Wainwright set a $9.00 target price on shares of Evoke Pharma and gave the stock a “buy” rating in a research report on Friday, August 17th. ValuEngine downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Friday, August 17th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.35.
In other Evoke Pharma news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was bought at an average cost of $2.35 per share, with a total value of $1,175,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 11.94% of the company’s stock.
Shares of NASDAQ EVOK opened at $2.65 on Friday. Evoke Pharma has a 1-year low of $1.85 and a 1-year high of $4.09. The stock has a market cap of $50.36 million, a PE ratio of -3.19 and a beta of 1.46.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Read More: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.